By ED SILVERMAN
The report represents the latest effort by payers to push back against the pharmaceutical industry over the cost of medicines. Over the past year, in particular, insurers and pharmacy benefit managers have sought to draw more attention to price tags as a way of placing pressure on drug makers.
Prices for various medicines – notably, new specialty treatments for hepatitis C and some forms of cancer – have generated substantial controversy as payers, both public and private, complain the drugs are budget busters. Avalere points to IMS Health data showing specialty medicines accounted for 78% of the $20.2 billion increase in new spending on brand-named drugs in 2014.
Prices for various medicines – notably, new specialty treatments for hepatitis C and some forms of cancer – have generated substantial controversy as payers, both public and private, complain the drugs are budget busters. Avalere points to IMS Health data showing specialty medicines accounted for 78% of the $20.2 billion increase in new spending on brand-named drugs in 2014.
No comments:
Post a Comment